07:41 AM EST, 02/23/2026 (MT Newswires) -- Armata Pharmaceuticals ( ARMP ) said Monday the US Food and Drug Administration has granted its experimental AP-SA02 candidate for intravenous use as a qualified infectious disease product for adjunct treatment of complicated bacteremia.

The designation covers bacteremia caused by methicillin-sensitive Staphylococcus aureus or methicillin resistant S. aureus.

The designation makes the product eligible for fast track status, paving the way for more frequent meetings and communication with the FDA, priority and rolling review, resulting in potential accelerated approval of its biologics license application, the company said.